// App-Quantinova.ai

762 : First-in-human phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR)

Researchers

Presenter

  • George Simon

Principal Investigators

  • Vivek Subbiah

  • Lee Rosen

  • Heinz-Josef Lenz

  • Haeseong Park

  • Minesh Patel

  • David Miles

  • Stephanie Wallis

  • Vladimir Evilevitch

  • David Krige

  • Mark Powell

  • Tom Lillie

Medical Centers

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Washington University, St Louis, MO

  • UCLA Medical Center, Los Angeles

  • PsiOxus Therapeutics Ltd, Abingdon, Oxford, UK

  • 1.MD Anderson Cancer Center, Houston, TX

  • H Lee Moffitt Cancer Center, Tampa FL and Advent Health Research Institute, Celebration, Tampa, FL, USA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Epithelial tumors

  • STAR syndrome

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • PsiOxus Therapeutics Limited

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved